Intravenous Immunoglobulin Therapy in Guillain-Barre Syndrome

J Korean Neurol Assoc > Volume 12(4); 1994 > Article

Journal of the Korean Neurological Association 1994;12(4): 709-714.

Guillain-Barre 증후군에서 경정맥 Immunoglobulin의 치료

조경원, 정원영,나정균,임건한

조선대학교 신경과.

Intravenous Immunoglobulin Therapy in Guillain-Barre Syndrome

Kyung Won Cho, M.D., Won Young Jung, M.D., Jeong Gyun Na, M.D., and Gun Han Lim, M.D.

Department of Neurology, Chosun University Medical College

Abstract

High dose intravenous immunoglobulin (IVIg) therapy can improve the clinical course of several immune mediciated diseases. We evaluated clinical effects and side effects of IVIg in Guillain-Barre syndrome (GBS). 19 Patients with GBS were studied prospectively in a placebo-controlled trial. 11 Patients were received high dose IVIg (400mg/kg for 5 days) and controls received only conservative treatment. The disability scores using modified Rankin scores before and after treatment of each group were compared. Four weaks later, mean Rankin Score of IVIg group was 2.5 + 0.7 and control group was 3.3+ 0.5which showed significant difference(p<0.05). There were no serious advers effer of promote early improvement with safety in acute phase of Guillan-Barre syndrome.